Letter no. 129

Ever wondered how well we truly grasp the companies we invest in? In today’s ET article, we look at Amgen, a US biotech giant that soared to success with one blockbuster drug, only to hit flatline for over a decade! How Amgen discovered that drug is even more intriguing. With limited corporate insights and an unpredictable future, managing a margin of safety is paramount. Join us today as we explore the repercussions of disregarding this principle – both theoretically, through DCF model and practically, through the events of 2008.

Read here: http://tinyurl.com/mw37az7j

Our previous articles can be found here:  https://www.buoyantcap.com/our-memos/

Disclaimer:

Information in this letter is not intended to be, nor should it be construed as investment, tax or legal advice, or an offer to sell, or a solicitation of any offer to make investments with Buoyant Capital. Prospective investors should rely solely on the Disclosure Document filed with SEBI. Any description involving investment examples, statistical analysis or investment strategies is provided for illustration purposes only – and will not apply in all situations and may be changed at the discretion of the principal officer. Certain information has been provided and/or based on third-party sources and although believed to be reliable, has not been independently verified; the investment managers make no express warranty as to its completeness or accuracy, nor can it accept responsibility for errors appearing herein.